A new blood test developed by Peter Hwang, a physician at the University of Alberta in Canada, can differentiate between a heart attack and heart strain, facilitating appropriate diagnosis and treatments for patients.

According to the researcher, the existing cardiac troponin blood test, which is the current gold standard for myocardial infarction diagnosis, does not highlight the exact extent of cardiac damage.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Elevated blood levels of the cardiac troponin protein that is found only in the heart are said to indicate heart damage. Hwang found that patients suffering from an actual heart attack had more fragmented troponin compared to those with increased cardiac strain.

“While further research is required, the physician believes that the new troponin test could direct objective treatment decisions in the case of less clear-cut situations.”

Hwang said: “We postulated that when cells die during a heart attack, not only would they release troponin into the bloodstream, but they would also digest the troponin through the action of activated intracellular proteases-enzymes that digest other proteins.”

During a study of 29 patients with elevated troponin levels, it was observed that the degree of proteolytic digestion was more when the severity of heart injury increased. Highest digestion was found in patients with ‘classic heart attack’ and least in those with a strain on the heart.

While further research is required, the physician believes that the new troponin test could direct objective treatment decisions in the case of less clear-cut situations.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

He added: “Sometimes the correct answer to the question – is it a heart injury or merely strain? – isn’t always obvious, even with all the clinical information.

“Suppose there is a critically ill patient with an elevated troponin level. Is the patient having a heart attack? Or is the troponin level elevated because the heart is working hard?

“This is a very real diagnostic dilemma faced by doctors treating patients. This test could resolve the challenge.”

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
HemoSonics has won the 2025 Marketing Award for its impactful promotion of theQuantra Hemostasis System and leadership in blood management education. See how targeted campaigns, thought leadership content, and hands on clinician training are accelerating Quantra’s market traction and shaping the future of hemostasis testing.

Discover the Impact